ClinicalTrials.gg
RecruitingNCT06714409VExOUS-ADHFUpdated Dec 3, 2024

Venous Ultrasound Guided Organ Decongestion in Patients Hospitalized with Acute Decompensated Heart Failure

An interventional study of VExUS guided decongestion in Cardiorenal Syndrome, Heart Failure and Acute Kidney Injury, sponsored by Oslo University Hospital. Recruiting at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-03.

Sponsored by Oslo University Hospital · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the feasibility, safety and effectiveness of VExUS guided organ decongestion compared to standard of care in patients hospitalized with acute decompensated heart failue (ADHF).

180 patients will be randomly assigned to either intervention (VExUS) arm or standard of care (SOC) arm. In the intervention arm, the treatment team will be informed by the study team about the results of the VExUS examination to supplement the clinical decision of proper decongestion treatment, while no information will be provided in the standard of care arm. Study visits are scheduled every second day while hospitalized, end of study is set to day of discharge from the ward. Telephone consultation and review of medical journal scheduled after 6 months to assess exploratory endpoints.

The overall rationale of the the study is to investigate if venous organ congestion investigated by VExUS score, is a modifiable risk factor in patients hospitalized with ADHF. And secondary to assess if venous organ decongestion guided by VExUS score may safely be implemented in patients hospitalized with ADHF and result in:

  • differences in length of hospitalization
  • changes in biomarkers of cardiac strain
  • changes in renal function and markers of renal injury
  • achieved doses of heart failure treatment at discharge
  • in-hospital complications

Safety measures with special attention on symptomatic hypotension, arrhythmias, metabolic alkalosis and electrolyte disturbances will be addressed.

02

Conditions studied

  • Cardiorenal Syndrome
  • Heart Failure
  • Acute Kidney Injury
  • Acute Decompensated Heart Failure

Keywords

  • Cardiorenal syndrome
  • Acute kidney injury
  • Heart failure
  • VExUS
  • Venous congestion
03

In context

Cardio-Renal Syndrome

85 studies on the registry are indexed under Cardio-Renal Syndrome; 20 are open to participants now.

This study's planned enrollment of 180 is above the median of 50 across 55 interventional studies indexed under Cardio-Renal Syndrome.

Browse Cardio-Renal Syndrome studies →

Lead sponsor

Oslo University Hospital is the lead sponsor of 835 studies on the registry; 148 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or above
  • Admitted the ward of Department of Cardiology OUH Ullevål with a clinical diagnosis of ADHFdefined by European Society of Cardiology
  • Pro-BNP > 800 ng/l at first day of admission
  • Capable of giving signed

Exclusion criteria

Exclusion Criteria:

  • Any medical or psychiatric condition which in the opinion of the investigatorprecludes participation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Intervention arm

    Patients in the intervention arm will undergo VExUS examinations at 1st day of inclusion, every other day while hospitalized and at discharge. The results from the VExUS examination (VExUS score) will be provided to the treatment team and the treatment team decides the individual treatment regime based on available information, with the overall goal to optimize decongestionand HF treatment according to current hospital standards. Safety issues and AEs will be assessed.In both gropus echocardiography will be performed at least once during the hospital stay.

    Diagnostic Test: VExUS guided decongestion

  • No intervention
    Standard of care

    Patients will undergo VExUS examinations at 1st day of inclusion and at discharge. The results from the VExUS examinations (VExUS score) will NOT be provided to the treatment team. They will be treated and followed up according to standard of care. In both gropus echocardiography will be performed at least once during the hospital stay.

Interventions

  • Diagnostic testVExUS guided decongestion

    Treatment team will be provided information about venous organ congestion status.

06

What researchers measure

Primary outcomes

  1. Change in VExUS score

    The findings from Doppler ultrasonography of the hepatic vein, portal vein, and interlobar renal vein will be graded using the VExUS score, which reflects the degree of venous congestion. The scale ranges from 0 to 3, where a score of 0 indicates no signs of congestion, 1 indicates mild congestion, 2 indicates moderate congestion, and 3 indicates severe congestion.

    Time frame: From the time of enrollment until hospital discharge, typically ranging from 3 to 21 days.

Secondary outcomes

  1. Change in NT-ProBNP

    Change in biomarker NT-ProBNP in serum.

    Time frame: From the time of enrollment until hospital discharge, typically ranging from 3 to 21 days.

  2. Change in estimated renal glomerular filtration rate

    Estimated glomerular filtration rate (eGFR) is calculated based on serum creatinine, age and gender.

    Time frame: From the time of enrollment until hospital discharge, typically ranging from 3 to 21 days.

  3. Change in urine albumin creatinine ratio

    Urine albumin creatinine is measured in spot urine sample.

    Time frame: From the time of enrollment until hospital discharge, typically ranging from 3 to 21 days.

  4. Change in symptoms

    Participants are asked to grade their symptoms using a 7-point Likert scale ranging from 1 to 7, where 1 indicates markedly better, 4 indicates no change, and 7 indicates markedly worse. Additionally, participants are asked to report their general condition and level of dyspnea on a Visual Analogue Scale (VAS) where 0 is negative and 100 is positive.

    Time frame: From the time of enrollment until hospital discharge, typically ranging from 3 to 21 days.

  5. Length of hospitalization

    Number of days from inclusion to discharge from hospital.

    Time frame: From the time of enrollment until hospital discharge, typically ranging from 3 to 21 days.

  6. Achieved dosage of HF medications at discharge

    Current heart failure medication compared to target dose in the national recommendations of HF-patient population.

    Time frame: From the time of enrollment until hospital discharge, typically ranging from 3 to 21 days.

  7. Safety

    Rates of symptomatic hypotension,worsening renal function, arrhythmias, severe metabolic alkalosis and electrolyte disturbances

    Time frame: From the time of enrollment until hospital discharge, typically ranging from 3 to 21 days.

07

Study locations

1 of 1 sites recruiting
  • Department of Nephrology, Oslo University Hospital
    Oslo, 0424, Norway
    Recruiting
08

References and documents

Publications

  • Longino A, Martin K, Leyba K, Siegel G, Thai TN, Riscinti M, Douglas IS, Gill E, Burke J. Prospective Evaluation of Venous Excess Ultrasound for Estimation of Venous Congestion. Chest. 2024 Mar;165(3):590-600. doi: 10.1016/j.chest.2023.09.029. Epub 2023 Oct 7. PubMed 37813180 ↗
  • Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol. 2009 Feb 17;53(7):582-588. doi: 10.1016/j.jacc.2008.08.080. PubMed 19215832 ↗
  • Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WHW. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009 Feb 17;53(7):589-596. doi: 10.1016/j.jacc.2008.05.068. PubMed 19215833 ↗
  • Beaubien-Souligny W, Rola P, Haycock K, Bouchard J, Lamarche Y, Spiegel R, Denault AY. Quantifying systemic congestion with Point-Of-Care ultrasound: development of the venous excess ultrasound grading system. Ultrasound J. 2020 Apr 9;12(1):16. doi: 10.1186/s13089-020-00163-w. PubMed 32270297 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2024 (actual). Primary completion is estimated for Oct 2025, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2024
First posted
Dec 3, 2024
StartActual
Sep 16, 2024
Primary completionEst.
Oct 1, 2025
CompletionEst.
Oct 1, 2025
Last update
Dec 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06714409
Collaborators
University of Oslo
Responsible party
Bård Waldum-Grevbo (Medical professor, MD, PhD, Oslo University Hospital) — Principal investigator
First posted
Dec 3, 2024
Start date
Sep 16, 2024
Primary completion
Oct 1, 2025 (estimated)
Completion
Oct 1, 2025 (estimated)
Last update
Dec 3, 2024

Study contacts

Bård Waldum-Grevbo, MD, PhD
Contact
uxwabr@ous-hf.no
+4722119220
Liv M Jacobsen, MD
Contact
uxjaiv@ous-hf.no
+4722119199

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion